Waverley Pharma, Inc.

  • Market Cap: N/A
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: CA94357L1058
CAD
0.02
0.01 (33.33%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryCompany CV
About Waverley Pharma, Inc. stock-summary
stock-summary
Waverley Pharma, Inc.
Pharmaceuticals & Biotechnology
Waverley Pharma Inc is a Canada-based company engaged in Biotechnology & Medical Research sector.The Company is focused on developing and commercializing Safe and Effective Small Molecules for Treatment of Cancer. Waverley Pharma is working in collaboration with a Indian conglomerate based in Mumbai to develop products for the treatment of cancer. Two of the lead products under developments are: WAV-101: WAV-101 is an injectable generic chemotherapy drug development for the treatment of non-small cell lung cancer and other indications; WAV-102 is also an injectable generic chemotherapy drug developed for the treatment of multiple myeloma and other indications. The Company has signed an agreement with Omgene Life Sciences for the development of another generic anti-cancer product WAV-103.
Company Coordinates stock-summary
Company Details
4-1250 Waverley St , WINNIPEG MB : R3T 6C6
Registrar Details
stock-recommendation Shareholding
Shareholding Snapshotstock-summary
Icon
No data for shareholding present.
Shareholding Compare (%holding) stock-summary
Icon
No data for shareholding present.
stock-summary Board of Directorsstock-summary
Management
Designation
Dr. Albert Friesen
Chairman of the Board
Mr. Pieter De Visser
Chief Financial Officer, Director
Mr. P. Marcus Enns
Independent Director
Ms. Hellen Siwanowicz
Independent Director
stock-recommendation Stock DNA
Revenue and Profits:
Net Sales:
0 Million
(Quarterly Results - Jun 2025)
Net Profit:
0 Million
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

CAD 1 Million ()

stock-summary
P/E

NA (Loss Making)

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

-1.32

stock-summary
Return on Equity

18.80%

stock-summary
Price to Book

-0.51